I provide independent and original analysis, pricing metrics and recommendations for the stem, cell, gene and regenerative therapy equities.

RegMed Investors (RMi) Financial results/Earnings Scorecard - Q2/2016 - to date

August 26, 2016

A ‘scorecard’ of public stem, cell, gene and regenerative therapy’s companies …  

Cesca Therapeutics Inc. (KOOL) cleans up the balance sheet with debt conversion

August 25, 2016

A good move re debt,  probably forced; increases dilution (6.1 M shares) hurting share pricing as well as Boyalife's "control". Stock DOWN -24% in pre-market ...  

Northwest Bio (NWBO) reprices warrants to raise cash

August 23, 2016

Raises $1.279 M as the stock price dumps -$0.06 to $0.34. The question is how long will this tranche of cash forestall insolvency? NWBO’s “saga” rolls on.  

Roll Call

The process of calling out our grading of covered companies to rank and review the facts in evidence together with analysis, opinion and objective recommendation.